Regeneron (REGN) Tops Q3 EPS by 14c, Beats on Revenues

November 8, 2017 6:36 AM EST
Get Alerts REGN Hot Sheet
Price: $534.27 -0.68%

EPS Growth %: +49.8%

Financial Fact:
Total expenses: 857.32M

Today's EPS Names:
More
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.99, $0.14 better than the analyst estimate of $3.85. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.46 billion.

  • Third quarter 2017 EYLEA┬« (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016
  • Third quarter 2017 EYLEA global net sales(1) increased 15% to $1.52 billion versus third quarter 2016
  • Third quarter 2017 GAAP net income per diluted share increased 46% to $3.32 versus third quarter 2016. Third quarter 2017 non-GAAP net income per diluted share increased 27% to $3.99 versus third quarter 2016.
  • Phase 3 EYLEA PANORAMA study for the treatment of diabetic retinopathy is fully enrolled with U.S. regulatory submission expected in 2018
  • Appellate court ordered a new trial and vacated permanent injunction in U.S. Praluent┬« patent case

For earnings history and earnings-related data on Regeneron (REGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings